Abstract
Ifosfamide, whether in single or combination regimen, have been used in many centers for end-stage cervical cancer cases or recurrent cases. Although it has shown satisfying results, especially in cases of platinum resistance, this drug is related to various side effects, such as encephalopathy. In this study, several cases of acute encephalopathy in cervical cancer patients treated with ifosfamide chemotherapy are described. This study is a retrospective study using all cervical cancer cases receiving ifosfamide chemotherapy in Sanglah Hospital Denpasar from 2015 to 2017. The diagnosis of encephalopathy was established by neurologists. Data obtained from hospital medical records. There were five patients who received the second line ifosfamide-cisplatin chemotherapy regimen at Sanglah Hospital Denpasar from 2015 to 2017. They had received first-line chemotherapy in form of 6 series of paclitaxel carboplatin and some of them received additional therapy in the form of external radiation and brachytherapy. Ifosfamide-cisplatin chemotherapy was given from one to six series, depending on the patient's response. Side effects in the form of encephalopathy appeared in four patients, while one patient managed to recover. Ifosfamide encephalopathy is a side effect that needs to be monitored. It has varied symptoms, but the symptoms are generally mild. Analysis of patient risk factors, patient education, and preparation for the management of encephalopathy should be performed in all cases that will receive ifosfamide. Methylene blue and thiamine can be used as a prophylactic and therapeutic choice for this condition.
Highlights
Cervical cancer ranks the second most common cause of death due to cancer in women which causes 275,000 deaths each year
We describe a series of cases of encephalopathy found in patients with cervical cancer who received ifosfamide chemotherapy
Ifosfamide-cisplatin combination chemotherapy is given for end-stage cervical cancer cases or recurrent cases that have been clinically established and supported by gyneco-oncologists
Summary
Cervical cancer ranks the second most common cause of death due to cancer in women which causes 275,000 deaths each year. The recurrent cases are resistant to platinum-based agents, causing unsatisfactory responses in some cases Ifosfamide, both as a single regimen and a combination has been used in many centers and shows a satisfactory response.. We describe a series of cases of encephalopathy found in patients with cervical cancer who received ifosfamide chemotherapy. This is a retrospective study conducted at Sanglah Hospital Denpasar, Bali, Indonesia. Ifosfamide-cisplatin combination chemotherapy is given for end-stage cervical cancer cases or recurrent cases that have been clinically established and supported by gyneco-oncologists.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
